What is Neurocrine Biosciences, Inc.'s Shariah compliance score?

Neurocrine Biosciences, Inc. (NBIX) has a Shariah compliance score of 73/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Neurocrine Biosciences, Inc. pass AAOIFI screening?

Neurocrine Biosciences, Inc. (NBIX) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (NBIX: 2.6%), (3) interest-bearing deposits below 30% (NBIX: 6.0%), and (4) prohibited income below 5% (NBIX: 3.9%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Neurocrine Biosciences, Inc. stock?

Neurocrine Biosciences, Inc. (NBIX) has a non-permissible income ratio of 3.94%. Muslim investors should purify this percentage of any dividends received and capital gains realized from NBIX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Neurocrine Biosciences, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Neurocrine Biosciences, Inc. (NBIX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about NBIX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Neurocrine Biosciences, Inc. (NBIX) halal? Halal. Based on AAOIFI screening, Neurocrine Biosciences, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 73/100 (Grade: B+).

NBIX: Is Neurocrine Biosciences, Inc. Halal?

Halal

Neurocrine Biosciences, Inc.

NASDAQHealthcareUS

$163.88

-2.07%

AvoidBorderlineClean

Purify ~3.9% of income

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 15, 2026

B+

Good

Good compliance with minor concerns

73Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap2.6% / 30.0%

Compliance History

Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 15, 2026Fiscal: Q1 2026Source: EDGAR

Purify Your NBIX Dividends

3.9% non-compliant income

NBIX has 3.9% prohibited income. Calculate exactly how much of your dividends to donate.

Financial Overview

Market Cap

16.5B

Price

$163.88

Sector

Healthcare

Industry

Biotechnology

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track NBIX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. (NBIX) halal to invest in?

Based on AAOIFI Standard 21 screening, Neurocrine Biosciences, Inc. (NBIX) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Neurocrine Biosciences, Inc. get a B+ compliance rating?

Neurocrine Biosciences, Inc. (NBIX) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.6% (limit 30%); interest-bearing deposits of 6.0% (limit 30%); prohibited income of 3.94% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Neurocrine Biosciences, Inc.'s Shariah verdict?

Neurocrine Biosciences, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Neurocrine Biosciences, Inc. re-screened for Shariah compliance?

Neurocrine Biosciences, Inc. (NBIX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.